Corvus Pharmaceuticals Set to Engage with Investors
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a leading player in the biopharmaceutical industry, is excited to share that its leadership team will participate in engagements with investors and take part in a fireside chat at a prominent healthcare conference.
Fireside Chat Details
This noteworthy event will take place during the Guggenheim 2nd Annual Healthcare Innovation Conference, aiming to shed light on innovative approaches in the biopharmaceutical field. Investors can look forward to the fireside chat scheduled for a specific time, offering insights into Corvus' strategic vision and ongoing projects.
Accessible Webcast for Broader Outreach
For those unable to attend in person, Corvus is providing a webcast of the fireside chat, ensuring that insights shared during the discussion are accessible to a wider audience. The webcast will not only be available live but can also be accessed for up to 90 days after the event, allowing participants to engage with the content at their convenience.
Overview of Corvus Pharmaceuticals
Corvus Pharmaceuticals is at the forefront of developing innovative therapeutic solutions that hold promise for treating various cancer and immune-related diseases. The company is pioneering the use of ITK inhibition in immunotherapy, introducing a novel approach to combat these complex ailments. Their flagship candidate, soquelitinib, represents a significant advancement in this area, showcasing their commitment to driving progress in biopharmaceutical development.
Connect with Corvus Pharmaceuticals
As part of its ongoing commitment to transparency and communication, Corvus encourages stakeholders to reach out for further information or inquiries. The investor relations section on the company’s website serves as a comprehensive resource for updates and developments.
Contact Information for Inquiries
For those interested in more detailed discussions or inquiries, Leiv Lea, the Chief Financial Officer, is available for contact. Additionally, Corvus maintains open communication channels for media inquiries, showcasing their investment in fostering relationships with stakeholders.
Frequently Asked Questions
What is the purpose of Corvus Pharmaceuticals' participation in the conference?
Corvus Pharmaceuticals aims to engage with investors to share insights into their innovative therapies and future directions.
When is the fireside chat scheduled?
The fireside chat will be held on a specific day and time during the conference.
How can investors access the webcast?
The webcast will be available live and can be accessed for 90 days post-event through the Corvus website.
What is soquelitinib?
Soquelitinib is Corvus Pharmaceuticals' investigational drug that selectively inhibits ITK, targeting cancer and immune diseases.
Who can I contact for more information about Corvus Pharmaceuticals?
Interested individuals can contact Leiv Lea, the Chief Financial Officer, or reach out through the media contact listed in the announcement.
